NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

XOMA Royalty Corp (XOMA) Stock Analysis

XOMA Royalty Corp (XOMA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

XOMA

$40.17

$0.00 (0.00%)

Last trade July 21, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XOMA with… →

XOMA Key Statistics

As of Jul 21, 2026
Trading
Open
$40.17
Previous Close
$40.17
52-Week Range
22.29–45.22
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.86
Valuation
Market Cap
$710.16M
P/E Ratio
25.59
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
18.77
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.63
EPS (ttm)Profit attributable to each share over the last twelve months.
1.57
Financials (FY)
Revenue (FY)
$11.66M+14.09%
Net Income (FY)
$31.71M
Profit marginThe share of revenue left as profit after all costs and taxes.
69.63%
1-Year Return
+57.65%
Dividend and dates
Avg Volume
329.33K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XOMA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+51.07%
2025+1.18%
2024 (partial year)+4.66%

As of July 21, 2026.

XOMA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$11.66M$31.71M272.0%
2024$10.22M−$13.82M−135.2%
2023$4.76M−$40.83M−858.2%
2022$6.03M−$17.10M−283.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$11.66M—$11.38M$31.71M272.0%
2024$10.22M—−$39.98M−$13.82M−135.2%
2023$4.76M—−$23.46M−$40.83M−858.2%
2022$6.03M—−$17.41M−$17.10M−283.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XOMA Valuation vs Biotechnology Median

Median of 656 stocks
MetricXOMABiotechnology medianvs median
P/E25.5912.57104% above
P/S ratio14.6315.264% below
Profit margin69.63%0.00%69.6 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

XOMA Royalty Corp (XOMA) is capitalised at $710.16M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 14.

Over the past 52 weeks the price has ranged from $22.29 to $45.22. XOMA last closed at $40.17 on July 21, 2026. The close was unchanged from the previous session. The latest close sits 80.22% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $11.66M. Against the prior fiscal year total of $10.22M, that is a change of +14.09%. Net income for the same year was $31.71M. Profit margin runs at 69.63%. That is 69.6 percentage points above the Biotechnology median of 0%. Trailing earnings per share are 1.57.

Across the 4 fiscal years on file, revenue moves from $6.03M in 2022 to $11.66M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 25.59. That is 103.58% above the Biotechnology median of 12.57. The forward P/E on file is 18.77. The price-to-sales ratio is 14.63. On price-to-sales that is 4.18% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.87. Daily returns over the trailing 1 year annualize to a volatility of 52.32%. Over the trailing twelve months the price has returned +57.65%. The stored price history starts on December 19, 2024, and the total return since then is +59.98%.

Growth & Income

The record shows no dividend for XOMA.

So far in 2026 the price is +51.07%. The record holds one complete calendar year, 2025, which returned +1.18%.

Peer Comparison

XOMA Royalty Corp (XOMA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
XOMA Royalty Corp XOMA $710.16M 25.6
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. XOMA Royalty Corp trades at a P/E of 25.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of July 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About XOMA Royalty Corp

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California. As of July 14, 2026, XOMA Royalty Corporation operates as a subsidiary of Ligand Pharmaceuticals Incorporated.

Visit website →